Lightning Round: Nokia is up against a lot of tough companies, says Jim Cramer

Key Concepts

• Voyager Technologies: A company operating in the space and national security sectors, considered a speculative investment.
• Immunome: A clinical-stage biotech company developing targeted cancer therapies, characterized by high volatility and financial losses.
• Nokia: A telecommunications company facing strong competition, particularly from Apple, but considered resilient.
• Apple (AAPL): A technology company experiencing a recent price dip, identified as a potential buying opportunity.
• Picker X-Ray (Against the Grain): A formerly high-growth company now undervalued, suggested as a potential long-term investment.
• Charles Schwab: Sponsor of the “Lightning Round” segment.
• Market Pessimism (2025 Tariffs): The incorrect prediction of market decline due to tariff policies.

Lightning Round Stock Discussions & Market Commentary

The segment, termed the “Lightning Round,” features rapid-fire questions from callers regarding specific stock investments, followed by Jim Cramer’s immediate reactions and advice. The round is sponsored by Charles Schwab.

Voyager Technologies Analysis: The first caller, Danny from Wisconsin, inquired about Voyager Technologies. Cramer identified the company’s involvement in the “space and national security” sectors as positive attributes, categorizing it as a “very good speculation.” This suggests a high-risk, potentially high-reward investment profile.

Immunome – Biotech Volatility & Risk: John from California discussed Immunome, a clinical-stage biotech firm focused on “targeted cancer therapies.” Cramer acknowledged the inherent “extreme volatility” and significant financial losses (“losing so much money”) typical of biotech companies. He referenced Dr. Siegel (presumably a medical professional from Seattle) as a potential source of expertise, but ultimately framed investment in Immunome as pure “speculation,” explicitly stating it shouldn’t be considered a core investment. This highlights the high-risk nature of investing in companies still in the clinical trial phase.

Nokia’s Resilience in a Competitive Market: Roy from Pennsylvania transitioned the conversation to Nokia, praising its resilience despite facing intense competition from companies like Apple. Cramer concurred, emphasizing Nokia’s strength stems from navigating a challenging landscape (“up against Apple. It’s up against a lot of different great companies”). He noted Apple’s recent stock decline (“Apple was down badly today”), identifying a price of “down four bucks” as a potential entry point for buying Apple stock, advocating a “buy a little Apple…buy some more” strategy as the price potentially decreases further. This demonstrates a dollar-cost averaging approach.

Personal Recommendation & Picker X-Ray’s Potential: Rebecca from New York briefly deviated to recommend a Holocaust history book ("The Delayed Life by the Krauss") to Cramer, referencing a previous discussion at the 92nd Street Y. She then inquired about “Picker X-Ray” (also known as Against the Grain). Cramer recognized the company’s past as a “very expensive growth company” now trading at a low valuation, perceiving “absolute value” in the current price. He explicitly recommended viewers “buy some and put it away,” suggesting a long-term investment horizon.

Concluding Remarks & Transition: Cramer concluded the “Lightning Round,” signaling a transition to a discussion about economic predictions. He stated, “The bears said tariff policies would ruin the market in 2025, but instead we saw gains across the board,” setting the stage for an analysis of why pessimistic forecasts regarding tariffs proved inaccurate.

Technical Terms:

• Clinical-Stage Biotech: A biotechnology company whose potential drugs are undergoing clinical trials (testing on humans).
• Volatility: The degree of price fluctuation of a financial instrument (like a stock) over a given period. High volatility indicates greater risk.
• Speculation: Investing with a high degree of risk, often based on limited information or short-term market trends.
• Dollar-Cost Averaging: An investment strategy where a fixed amount of money is invested at regular intervals, regardless of the asset's price.

Logical Connections:

The segment follows a question-and-answer format, with each caller presenting a specific investment idea. Cramer responds with his assessment, often highlighting the risk-reward profile of each stock. The transition to the next segment is linked to a broader economic theme – the failure of pessimistic market predictions – building on the rapid-fire nature of the “Lightning Round” to introduce a more in-depth analysis.

Data & Statistics:

• Apple stock was “down four bucks” during the broadcast. (Specific dollar amount not provided, but indicates a recent price decrease).

Synthesis/Conclusion:

The “Lightning Round” provides a snapshot of investor sentiment and Cramer’s rapid-fire analysis of various stocks. The segment emphasizes the importance of understanding risk, particularly in volatile sectors like biotechnology. Cramer’s advice ranges from cautious speculation (Immunome) to identifying potential value in undervalued companies (Picker X-Ray) and capitalizing on temporary price dips in established companies (Apple). The overarching theme is informed speculation and a nuanced understanding of market dynamics.